CZ15015U1 - Farmaceutická kompozice s postupným uvolňováním - Google Patents

Farmaceutická kompozice s postupným uvolňováním Download PDF

Info

Publication number: CZ15015U1
Authority: CZ; Czechia
Prior art keywords: tamsulosin; pharmaceutical composition; layer; drug; release
Prior art date: 2003-11-10

Application number

CZ200415532U

Other languages

Czech (cs)

English (en)

Inventor

Kazuhiro Sako

Toyohiro Sawada

Keiichi Yoshihara

Hiroyuki Kojima

Original Assignee

Yamanouchi Pharmaceutical Co., Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-11-10

Filing date

2004-06-09

Publication date

2005-01-13

2004-06-09 Application filed by Yamanouchi Pharmaceutical Co., Ltd filed Critical Yamanouchi Pharmaceutical Co., Ltd

2005-01-13 Publication of CZ15015U1 publication Critical patent/CZ15015U1/cs

Links

239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 116
230000000750 progressive effect Effects 0.000 title 1
DRHKJLXJIQTDTD-OAHLLOKOSA-N Tamsulosine Chemical compound CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 DRHKJLXJIQTDTD-OAHLLOKOSA-N 0.000 claims abstract description 106
229960002613 tamsulosin Drugs 0.000 claims abstract description 102
238000013268 sustained release Methods 0.000 claims abstract description 100
239000012730 sustained-release form Substances 0.000 claims abstract description 100
238000000034 method Methods 0.000 claims abstract description 77
150000003839 salts Chemical class 0.000 claims abstract description 53
238000004090 dissolution Methods 0.000 claims abstract description 33
230000002411 adverse Effects 0.000 claims abstract description 29
230000037406 food intake Effects 0.000 claims abstract description 27
238000007922 dissolution test Methods 0.000 claims abstract description 26
239000003814 drug Substances 0.000 claims description 168
229940079593 drug Drugs 0.000 claims description 165
238000002360 preparation method Methods 0.000 claims description 106
229920000642 polymer Polymers 0.000 claims description 66
239000011347 resin Substances 0.000 claims description 36
229920005989 resin Polymers 0.000 claims description 36
230000000694 effects Effects 0.000 claims description 35
238000012360 testing method Methods 0.000 claims description 31
230000036470 plasma concentration Effects 0.000 claims description 27
235000012631 food intake Nutrition 0.000 claims description 25
229920003169 water-soluble polymer Polymers 0.000 claims description 25
230000003204 osmotic effect Effects 0.000 claims description 20
239000011159 matrix material Substances 0.000 claims description 14
230000008961 swelling Effects 0.000 claims description 8
210000002784 stomach Anatomy 0.000 claims description 7
229940068196 placebo Drugs 0.000 claims description 4
239000000902 placebo Substances 0.000 claims description 4
230000000717 retained effect Effects 0.000 claims description 3
ZZIZZTHXZRDOFM-UHFFFAOYSA-N 2-(2-ethoxyphenoxy)ethyl-[1-(4-methoxy-3-sulfamoylphenyl)propan-2-yl]azanium;chloride Chemical compound Cl.CCOC1=CC=CC=C1OCCNC(C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 ZZIZZTHXZRDOFM-UHFFFAOYSA-N 0.000 abstract description 103
229960003198 tamsulosin hydrochloride Drugs 0.000 abstract description 103
206010031127 Orthostatic hypotension Diseases 0.000 abstract description 13
239000003405 delayed action preparation Substances 0.000 abstract description 10
230000001965 increasing effect Effects 0.000 abstract description 10
235000013305 food Nutrition 0.000 abstract description 7
230000002829 reductive effect Effects 0.000 abstract description 5
206010067484 Adverse reaction Diseases 0.000 abstract description 3
230000006838 adverse reaction Effects 0.000 abstract description 3
239000010410 layer Substances 0.000 description 214
239000000203 mixture Substances 0.000 description 166
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 107
239000003826 tablet Substances 0.000 description 103
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 100
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 100
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 100
238000009472 formulation Methods 0.000 description 88
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 68
238000004519 manufacturing process Methods 0.000 description 64
235000002639 sodium chloride Nutrition 0.000 description 62
239000002245 particle Substances 0.000 description 61
229920003171 Poly (ethylene oxide) Polymers 0.000 description 43
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 43
239000011812 mixed powder Substances 0.000 description 42
-1 hydrochloric Chemical class 0.000 description 41
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 37
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 35
239000008101 lactose Substances 0.000 description 35
235000019359 magnesium stearate Nutrition 0.000 description 34
239000000126 substance Substances 0.000 description 33
229920002678 cellulose Polymers 0.000 description 32
239000004480 active ingredient Substances 0.000 description 31
239000001856 Ethyl cellulose Substances 0.000 description 30
239000001913 cellulose Substances 0.000 description 30
235000019325 ethyl cellulose Nutrition 0.000 description 30
229920001249 ethyl cellulose Polymers 0.000 description 30
239000012530 fluid Substances 0.000 description 30
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 29
235000010980 cellulose Nutrition 0.000 description 29
239000012528 membrane Substances 0.000 description 27
239000004570 mortar (masonry) Substances 0.000 description 26
239000000843 powder Substances 0.000 description 25
UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 24
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
239000007921 spray Substances 0.000 description 24
239000013563 matrix tablet Substances 0.000 description 21
239000000546 pharmaceutical excipient Substances 0.000 description 21
239000004359 castor oil Substances 0.000 description 19
235000019438 castor oil Nutrition 0.000 description 19
238000007906 compression Methods 0.000 description 19
230000006835 compression Effects 0.000 description 19
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 19
239000007864 aqueous solution Substances 0.000 description 18
239000002585 base Substances 0.000 description 18
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 17
239000000377 silicon dioxide Substances 0.000 description 17
239000000243 solution Substances 0.000 description 17
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 16
238000000748 compression moulding Methods 0.000 description 15
238000002156 mixing Methods 0.000 description 15
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 14
229930195725 Mannitol Natural products 0.000 description 14
239000008118 PEG 6000 Substances 0.000 description 14
229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 14
238000010521 absorption reaction Methods 0.000 description 14
239000000499 gel Substances 0.000 description 14
239000000314 lubricant Substances 0.000 description 14
239000000594 mannitol Substances 0.000 description 14
235000010355 mannitol Nutrition 0.000 description 14
229920001285 xanthan gum Polymers 0.000 description 14
239000003795 chemical substances by application Substances 0.000 description 13
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
229920002134 Carboxymethyl cellulose Polymers 0.000 description 12
229920000869 Homopolysaccharide Polymers 0.000 description 12
235000010948 carboxy methyl cellulose Nutrition 0.000 description 12
229920002301 cellulose acetate Polymers 0.000 description 12
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 11
229920000168 Microcrystalline cellulose Polymers 0.000 description 11
239000001768 carboxy methyl cellulose Substances 0.000 description 11
230000002209 hydrophobic effect Effects 0.000 description 11
235000019813 microcrystalline cellulose Nutrition 0.000 description 11
239000008108 microcrystalline cellulose Substances 0.000 description 11
229940016286 microcrystalline cellulose Drugs 0.000 description 11
239000008188 pellet Substances 0.000 description 11
230000002265 prevention Effects 0.000 description 11
102000005962 receptors Human genes 0.000 description 11
108020003175 receptors Proteins 0.000 description 11
GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical class C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 10
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 10
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
239000008112 carboxymethyl-cellulose Substances 0.000 description 10
229940105329 carboxymethylcellulose Drugs 0.000 description 10
239000011248 coating agent Substances 0.000 description 10
238000000576 coating method Methods 0.000 description 10
239000008119 colloidal silica Substances 0.000 description 10
230000001276 controlling effect Effects 0.000 description 10
JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 10
239000007788 liquid Substances 0.000 description 10
239000003921 oil Substances 0.000 description 10
235000019198 oils Nutrition 0.000 description 10
229920000036 polyvinylpyrrolidone Polymers 0.000 description 10
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 10
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 9
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
229920002125 Sokalan® Polymers 0.000 description 9
239000003085 diluting agent Substances 0.000 description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
238000001035 drying Methods 0.000 description 9
239000008187 granular material Substances 0.000 description 9
238000003760 magnetic stirring Methods 0.000 description 9
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 8
239000004354 Hydroxyethyl cellulose Substances 0.000 description 8
235000011132 calcium sulphate Nutrition 0.000 description 8
201000010099 disease Diseases 0.000 description 8
210000001035 gastrointestinal tract Anatomy 0.000 description 8
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 8
239000002357 osmotic agent Substances 0.000 description 8
239000011780 sodium chloride Substances 0.000 description 8
239000002904 solvent Substances 0.000 description 8
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 7
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 7
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 7
239000000654 additive Substances 0.000 description 7
230000000903 blocking effect Effects 0.000 description 7
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical group C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 7
239000008121 dextrose Substances 0.000 description 7
230000000977 initiatory effect Effects 0.000 description 7
229920001282 polysaccharide Polymers 0.000 description 7
239000005017 polysaccharide Substances 0.000 description 7
239000001267 polyvinylpyrrolidone Substances 0.000 description 7
239000000047 product Substances 0.000 description 7
229960002920 sorbitol Drugs 0.000 description 7
239000000758 substrate Substances 0.000 description 7
238000002560 therapeutic procedure Methods 0.000 description 7
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 6
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
229920002472 Starch Polymers 0.000 description 6
125000000217 alkyl group Chemical group 0.000 description 6
210000001124 body fluid Anatomy 0.000 description 6
239000010839 body fluid Substances 0.000 description 6
238000005469 granulation Methods 0.000 description 6
230000003179 granulation Effects 0.000 description 6
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 6
239000000463 material Substances 0.000 description 6
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 6
230000035699 permeability Effects 0.000 description 6
239000000825 pharmaceutical preparation Substances 0.000 description 6
229920000233 poly(alkylene oxides) Polymers 0.000 description 6
150000004804 polysaccharides Chemical class 0.000 description 6
235000019698 starch Nutrition 0.000 description 6
229940032147 starch Drugs 0.000 description 6
239000008107 starch Substances 0.000 description 6
238000005303 weighing Methods 0.000 description 6
OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 description 5
239000004971 Cross linker Substances 0.000 description 5
229920000926 Galactomannan Polymers 0.000 description 5
108010010803 Gelatin Proteins 0.000 description 5
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 5
208000001953 Hypotension Diseases 0.000 description 5
229930006000 Sucrose Natural products 0.000 description 5
229910052783 alkali metal Inorganic materials 0.000 description 5
239000011230 binding agent Substances 0.000 description 5
239000008280 blood Substances 0.000 description 5
210000004369 blood Anatomy 0.000 description 5
239000002775 capsule Substances 0.000 description 5
125000002091 cationic group Chemical group 0.000 description 5
239000000701 coagulant Substances 0.000 description 5
239000011247 coating layer Substances 0.000 description 5
210000001072 colon Anatomy 0.000 description 5
238000013270 controlled release Methods 0.000 description 5
230000004064 dysfunction Effects 0.000 description 5
RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
239000008273 gelatin Substances 0.000 description 5
229920000159 gelatin Polymers 0.000 description 5
239000007903 gelatin capsule Substances 0.000 description 5
235000019322 gelatine Nutrition 0.000 description 5
235000011852 gelatine desserts Nutrition 0.000 description 5
239000000017 hydrogel Substances 0.000 description 5
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 5
239000001863 hydroxypropyl cellulose Substances 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
239000003701 inert diluent Substances 0.000 description 5
230000007246 mechanism Effects 0.000 description 5
229920000609 methyl cellulose Polymers 0.000 description 5
239000001923 methylcellulose Substances 0.000 description 5
235000010981 methylcellulose Nutrition 0.000 description 5
229920001223 polyethylene glycol Polymers 0.000 description 5
239000000600 sorbitol Substances 0.000 description 5
235000010356 sorbitol Nutrition 0.000 description 5
238000003756 stirring Methods 0.000 description 5
239000005720 sucrose Substances 0.000 description 5
ZZIZZTHXZRDOFM-XFULWGLBSA-N tamsulosin hydrochloride Chemical compound [H+].[Cl-].CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 ZZIZZTHXZRDOFM-XFULWGLBSA-N 0.000 description 5
210000002438 upper gastrointestinal tract Anatomy 0.000 description 5
239000000230 xanthan gum Substances 0.000 description 5
235000010493 xanthan gum Nutrition 0.000 description 5
229940082509 xanthan gum Drugs 0.000 description 5
DQEFEBPAPFSJLV-UHFFFAOYSA-N Cellulose propionate Chemical compound CCC(=O)OCC1OC(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C1OC1C(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C(COC(=O)CC)O1 DQEFEBPAPFSJLV-UHFFFAOYSA-N 0.000 description 4
240000008886 Ceratonia siliqua Species 0.000 description 4
235000013912 Ceratonia siliqua Nutrition 0.000 description 4
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
229920000161 Locust bean gum Polymers 0.000 description 4
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
229920002565 Polyethylene Glycol 400 Polymers 0.000 description 4
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
235000021355 Stearic acid Nutrition 0.000 description 4
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 4
244000131415 Zanthoxylum piperitum Species 0.000 description 4
235000008853 Zanthoxylum piperitum Nutrition 0.000 description 4
UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical group CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 4
150000001340 alkali metals Chemical class 0.000 description 4
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
150000001720 carbohydrates Chemical class 0.000 description 4
150000001768 cations Chemical class 0.000 description 4
229920006218 cellulose propionate Polymers 0.000 description 4
239000003638 chemical reducing agent Substances 0.000 description 4
239000007884 disintegrant Substances 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
239000003623 enhancer Substances 0.000 description 4
239000008172 hydrogenated vegetable oil Substances 0.000 description 4
229920001477 hydrophilic polymer Polymers 0.000 description 4
230000036543 hypotension Effects 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical group O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 4
235000010420 locust bean gum Nutrition 0.000 description 4
239000000711 locust bean gum Substances 0.000 description 4
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 4
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 4
NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 description 4
239000004584 polyacrylic acid Substances 0.000 description 4
239000011591 potassium Substances 0.000 description 4
229910052700 potassium Inorganic materials 0.000 description 4
239000003087 receptor blocking agent Substances 0.000 description 4
230000001105 regulatory effect Effects 0.000 description 4
238000007086 side reaction Methods 0.000 description 4
239000011734 sodium Substances 0.000 description 4
229910052708 sodium Inorganic materials 0.000 description 4
239000008117 stearic acid Substances 0.000 description 4
150000005846 sugar alcohols Chemical class 0.000 description 4
238000013269 sustained drug release Methods 0.000 description 4
230000002459 sustained effect Effects 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
239000000811 xylitol Substances 0.000 description 4
235000010447 xylitol Nutrition 0.000 description 4
229960002675 xylitol Drugs 0.000 description 4
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 4
NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
IRIAEXORFWYRCZ-UHFFFAOYSA-N Butylbenzyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCC1=CC=CC=C1 IRIAEXORFWYRCZ-UHFFFAOYSA-N 0.000 description 3
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 3
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 3
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
230000002378 acidificating effect Effects 0.000 description 3
239000013543 active substance Substances 0.000 description 3
230000000996 additive effect Effects 0.000 description 3
238000005273 aeration Methods 0.000 description 3
235000010443 alginic acid Nutrition 0.000 description 3
239000000783 alginic acid Substances 0.000 description 3
229920000615 alginic acid Polymers 0.000 description 3
229960001126 alginic acid Drugs 0.000 description 3
150000004781 alginic acids Chemical class 0.000 description 3
125000003545 alkoxy group Chemical group 0.000 description 3
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 3
235000013539 calcium stearate Nutrition 0.000 description 3
239000008116 calcium stearate Substances 0.000 description 3
239000001175 calcium sulphate Substances 0.000 description 3
235000014633 carbohydrates Nutrition 0.000 description 3
229920003174 cellulose-based polymer Polymers 0.000 description 3
235000015165 citric acid Nutrition 0.000 description 3
229920001577 copolymer Polymers 0.000 description 3
235000014113 dietary fatty acids Nutrition 0.000 description 3
150000002148 esters Chemical class 0.000 description 3
MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 3
239000000194 fatty acid Substances 0.000 description 3
229930195729 fatty acid Natural products 0.000 description 3
239000010408 film Substances 0.000 description 3
229940093334 flomax Drugs 0.000 description 3
229930182830 galactose Natural products 0.000 description 3
239000008103 glucose Substances 0.000 description 3
YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 3
SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 3
230000036571 hydration Effects 0.000 description 3
238000006703 hydration reaction Methods 0.000 description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
229920003063 hydroxymethyl cellulose Polymers 0.000 description 3
229940031574 hydroxymethyl cellulose Drugs 0.000 description 3
210000000936 intestine Anatomy 0.000 description 3
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 3
210000003750 lower gastrointestinal tract Anatomy 0.000 description 3
229910001629 magnesium chloride Inorganic materials 0.000 description 3
235000011147 magnesium chloride Nutrition 0.000 description 3
230000027939 micturition Effects 0.000 description 3
150000007524 organic acids Chemical class 0.000 description 3
239000003960 organic solvent Substances 0.000 description 3
229940124531 pharmaceutical excipient Drugs 0.000 description 3
229920002451 polyvinyl alcohol Polymers 0.000 description 3
238000003825 pressing Methods 0.000 description 3
229940045902 sodium stearyl fumarate Drugs 0.000 description 3
239000007787 solid Substances 0.000 description 3
235000000346 sugar Nutrition 0.000 description 3
239000004094 surface-active agent Substances 0.000 description 3
239000007916 tablet composition Substances 0.000 description 3
239000000454 talc Substances 0.000 description 3
229910052623 talc Inorganic materials 0.000 description 3
235000012222 talc Nutrition 0.000 description 3
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
230000002485 urinary effect Effects 0.000 description 3
238000005550 wet granulation Methods 0.000 description 3
238000009736 wetting Methods 0.000 description 3
PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
FEBUJFMRSBAMES-UHFFFAOYSA-N 2-[(2-{[3,5-dihydroxy-2-(hydroxymethyl)-6-phosphanyloxan-4-yl]oxy}-3,5-dihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-4-yl)oxy]-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl phosphinite Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(OC2C(C(OP)C(O)C(CO)O2)O)C(O)C(OC2C(C(CO)OC(P)C2O)O)O1 FEBUJFMRSBAMES-UHFFFAOYSA-N 0.000 description 2
XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 2
NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
229920002126 Acrylic acid copolymer Polymers 0.000 description 2
239000004382 Amylase Substances 0.000 description 2
102000013142 Amylases Human genes 0.000 description 2
108010065511 Amylases Proteins 0.000 description 2
206010004446 Benign prostatic hyperplasia Diseases 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
229920001747 Cellulose diacetate Polymers 0.000 description 2
229920002284 Cellulose triacetate Polymers 0.000 description 2
229920001661 Chitosan Polymers 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
229920002307 Dextran Polymers 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
KCXZNSGUUQJJTR-UHFFFAOYSA-N Di-n-hexyl phthalate Chemical compound CCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCC KCXZNSGUUQJJTR-UHFFFAOYSA-N 0.000 description 2
NIQCNGHVCWTJSM-UHFFFAOYSA-N Dimethyl phthalate Chemical compound COC(=O)C1=CC=CC=C1C(=O)OC NIQCNGHVCWTJSM-UHFFFAOYSA-N 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
239000005715 Fructose Substances 0.000 description 2
229930091371 Fructose Natural products 0.000 description 2
229920001503 Glucan Polymers 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
229920000057 Mannan Polymers 0.000 description 2
CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
239000004793 Polystyrene Substances 0.000 description 2
239000004372 Polyvinyl alcohol Substances 0.000 description 2
208000004403 Prostatic Hyperplasia Diseases 0.000 description 2
229920002305 Schizophyllan Polymers 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
208000003443 Unconsciousness Diseases 0.000 description 2
208000026723 Urinary tract disease Diseases 0.000 description 2
NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
229910052784 alkaline earth metal Inorganic materials 0.000 description 2
229920013820 alkyl cellulose Polymers 0.000 description 2
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
235000019418 amylase Nutrition 0.000 description 2
150000008064 anhydrides Chemical class 0.000 description 2
239000003125 aqueous solvent Substances 0.000 description 2
239000008122 artificial sweetener Substances 0.000 description 2
235000021311 artificial sweeteners Nutrition 0.000 description 2
238000003556 assay Methods 0.000 description 2
TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
BJQHLKABXJIVAM-UHFFFAOYSA-N bis(2-ethylhexyl) phthalate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC BJQHLKABXJIVAM-UHFFFAOYSA-N 0.000 description 2
WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 2
DKPFZGUDAPQIHT-UHFFFAOYSA-N butyl acetate Chemical compound CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 2
125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
229960005069 calcium Drugs 0.000 description 2
239000011575 calcium Substances 0.000 description 2
239000001110 calcium chloride Substances 0.000 description 2
229910001628 calcium chloride Inorganic materials 0.000 description 2
235000011148 calcium chloride Nutrition 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
150000001721 carbon Chemical group 0.000 description 2
229950008138 carmellose Drugs 0.000 description 2
235000010418 carrageenan Nutrition 0.000 description 2
229920001525 carrageenan Polymers 0.000 description 2
239000000679 carrageenan Substances 0.000 description 2
229940113118 carrageenan Drugs 0.000 description 2
229920000891 common polymer Polymers 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
229940099112 cornstarch Drugs 0.000 description 2
238000011161 development Methods 0.000 description 2
SWXVUIWOUIDPGS-UHFFFAOYSA-N diacetone alcohol Chemical compound CC(=O)CC(C)(C)O SWXVUIWOUIDPGS-UHFFFAOYSA-N 0.000 description 2
150000005690 diesters Chemical class 0.000 description 2
FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
208000002173 dizziness Diseases 0.000 description 2
239000002355 dual-layer Substances 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
230000003628 erosive effect Effects 0.000 description 2
230000001747 exhibiting effect Effects 0.000 description 2
238000001125 extrusion Methods 0.000 description 2
150000004665 fatty acids Chemical class 0.000 description 2
239000004088 foaming agent Substances 0.000 description 2
230000009246 food effect Effects 0.000 description 2
239000003205 fragrance Substances 0.000 description 2
210000004907 gland Anatomy 0.000 description 2
238000000227 grinding Methods 0.000 description 2
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
239000008240 homogeneous mixture Substances 0.000 description 2
238000001746 injection moulding Methods 0.000 description 2
229910052744 lithium Inorganic materials 0.000 description 2
KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
229910052943 magnesium sulfate Inorganic materials 0.000 description 2
235000019341 magnesium sulphate Nutrition 0.000 description 2
230000014759 maintenance of location Effects 0.000 description 2
FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 2
235000011090 malic acid Nutrition 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
229940117841 methacrylic acid copolymer Drugs 0.000 description 2
229920003145 methacrylic acid copolymer Polymers 0.000 description 2
XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
150000002772 monosaccharides Chemical class 0.000 description 2
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
235000010987 pectin Nutrition 0.000 description 2
239000001814 pectin Substances 0.000 description 2
229920001277 pectin Polymers 0.000 description 2
239000012466 permeate Substances 0.000 description 2
238000009522 phase III clinical trial Methods 0.000 description 2
XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 2
239000004014 plasticizer Substances 0.000 description 2
229920001983 poloxamer Polymers 0.000 description 2
229920001467 poly(styrenesulfonates) Polymers 0.000 description 2
229920000136 polysorbate Polymers 0.000 description 2
229920000053 polysorbate 80 Polymers 0.000 description 2
229920002223 polystyrene Polymers 0.000 description 2
235000019422 polyvinyl alcohol Nutrition 0.000 description 2
IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 2
239000001103 potassium chloride Substances 0.000 description 2
235000011164 potassium chloride Nutrition 0.000 description 2
NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
229910000160 potassium phosphate Inorganic materials 0.000 description 2
235000011009 potassium phosphates Nutrition 0.000 description 2
OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 2
229910052939 potassium sulfate Inorganic materials 0.000 description 2
235000011151 potassium sulphates Nutrition 0.000 description 2
229960001289 prazosin Drugs 0.000 description 2
IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 2
230000008569 process Effects 0.000 description 2
125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 2
210000002307 prostate Anatomy 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
239000001509 sodium citrate Substances 0.000 description 2
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
235000011083 sodium citrates Nutrition 0.000 description 2
PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
229940035044 sorbitan monolaurate Drugs 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
206010042772 syncope Diseases 0.000 description 2
239000011975 tartaric acid Substances 0.000 description 2
235000002906 tartaric acid Nutrition 0.000 description 2
239000012085 test solution Substances 0.000 description 2
239000010409 thin film Substances 0.000 description 2
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
210000003708 urethra Anatomy 0.000 description 2
210000001635 urinary tract Anatomy 0.000 description 2
UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 description 1
YAXKTBLXMTYWDQ-UHFFFAOYSA-N 1,2,3-butanetriol Chemical compound CC(O)C(O)CO YAXKTBLXMTYWDQ-UHFFFAOYSA-N 0.000 description 1
KNKRKFALVUDBJE-UHFFFAOYSA-N 1,2-dichloropropane Chemical compound CC(Cl)CCl KNKRKFALVUDBJE-UHFFFAOYSA-N 0.000 description 1
229940058015 1,3-butylene glycol Drugs 0.000 description 1
LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
JSZOAYXJRCEYSX-UHFFFAOYSA-N 1-nitropropane Chemical compound CCC[N+]([O-])=O JSZOAYXJRCEYSX-UHFFFAOYSA-N 0.000 description 1
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
WHNBDXQTMPYBAT-UHFFFAOYSA-N 2-butyloxirane Chemical compound CCCCC1CO1 WHNBDXQTMPYBAT-UHFFFAOYSA-N 0.000 description 1
ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
GIOCILWWMFZESP-UHFFFAOYSA-N 2-hydroxyethyl butanoate Chemical compound CCCC(=O)OCCO GIOCILWWMFZESP-UHFFFAOYSA-N 0.000 description 1
UMNVUZRZKPVECS-UHFFFAOYSA-N 2-propanoyloxyethyl propanoate Chemical compound CCC(=O)OCCOC(=O)CC UMNVUZRZKPVECS-UHFFFAOYSA-N 0.000 description 1
GDCOAKPWVJCNGI-UHFFFAOYSA-N 4-methylnonan-4-ol Chemical compound CCCCCC(C)(O)CCC GDCOAKPWVJCNGI-UHFFFAOYSA-N 0.000 description 1
ADGOOVVFTLKVKH-UHFFFAOYSA-N 4-propanoyloxybutyl propanoate Chemical compound CCC(=O)OCCCCOC(=O)CC ADGOOVVFTLKVKH-UHFFFAOYSA-N 0.000 description 1
DMIMWGHYIPFAIF-UHFFFAOYSA-N 5-nitro-2-piperidin-1-ylaniline Chemical compound NC1=CC([N+]([O-])=O)=CC=C1N1CCCCC1 DMIMWGHYIPFAIF-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
108010011485 Aspartame Proteins 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
LOMRQGQGQBPCNO-XFFZJAGNSA-N C1(C=CC2=CC=CC=C12)/C(=C/C(=O)O)/C(=O)O Chemical compound C1(C=CC2=CC=CC=C12)/C(=C/C(=O)O)/C(=O)O LOMRQGQGQBPCNO-XFFZJAGNSA-N 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
244000025254 Cannabis sativa Species 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
235000008733 Citrus aurantifolia Nutrition 0.000 description 1
235000005979 Citrus limon Nutrition 0.000 description 1
244000131522 Citrus pyriformis Species 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
244000303965 Cyamopsis psoralioides Species 0.000 description 1
229920001560 Cyanamer® Polymers 0.000 description 1
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 1
WQZGKKKJIJFFOK-WHZQZERISA-N D-aldose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-WHZQZERISA-N 0.000 description 1
NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
ZVFDTKUVRCTHQE-UHFFFAOYSA-N Diisodecyl phthalate Chemical compound CC(C)CCCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCCC(C)C ZVFDTKUVRCTHQE-UHFFFAOYSA-N 0.000 description 1
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
208000021473 Ejaculation disease Diseases 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical class C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
229920002148 Gellan gum Polymers 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
206010020853 Hypertonic bladder Diseases 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
208000001089 Multiple system atrophy Diseases 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
208000000693 Neurogenic Urinary Bladder Diseases 0.000 description 1
206010029279 Neurogenic bladder Diseases 0.000 description 1
102000016979 Other receptors Human genes 0.000 description 1
208000009722 Overactive Urinary Bladder Diseases 0.000 description 1
235000021314 Palmitic acid Nutrition 0.000 description 1
206010033557 Palpitations Diseases 0.000 description 1
MURWRBWZIMXKGC-UHFFFAOYSA-N Phthalsaeure-butylester-octylester Natural products CCCCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC MURWRBWZIMXKGC-UHFFFAOYSA-N 0.000 description 1
229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 1
229920002538 Polyethylene Glycol 20000 Polymers 0.000 description 1
229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
229920000954 Polyglycolide Polymers 0.000 description 1
229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
206010041349 Somnolence Diseases 0.000 description 1
IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 1
244000228451 Stevia rebaudiana Species 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
208000001871 Tachycardia Diseases 0.000 description 1
235000011941 Tilia x europaea Nutrition 0.000 description 1
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
229920002310 Welan gum Polymers 0.000 description 1
229920002494 Zein Polymers 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
239000002250 absorbent Substances 0.000 description 1
230000002745 absorbent Effects 0.000 description 1
IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
QXNIBPDSSDVBQP-UHFFFAOYSA-N acetic acid;2-methylpropanoic acid Chemical compound CC(O)=O.CC(C)C(O)=O QXNIBPDSSDVBQP-UHFFFAOYSA-N 0.000 description 1
IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 description 1
PPBFVJQAQFIZNS-UHFFFAOYSA-N acetic acid;ethylcarbamic acid Chemical compound CC(O)=O.CCNC(O)=O PPBFVJQAQFIZNS-UHFFFAOYSA-N 0.000 description 1
ZGJVTOHMNLDNNU-UHFFFAOYSA-N acetic acid;heptanoic acid Chemical compound CC(O)=O.CCCCCCC(O)=O ZGJVTOHMNLDNNU-UHFFFAOYSA-N 0.000 description 1
OKTJLQBMTBEEJV-UHFFFAOYSA-N acetic acid;methylcarbamic acid Chemical compound CC(O)=O.CNC(O)=O OKTJLQBMTBEEJV-UHFFFAOYSA-N 0.000 description 1
UDJCTHZWTUFHSJ-UHFFFAOYSA-N acetic acid;octanoic acid Chemical compound CC(O)=O.CCCCCCCC(O)=O UDJCTHZWTUFHSJ-UHFFFAOYSA-N 0.000 description 1
239000003929 acidic solution Substances 0.000 description 1
230000009471 action Effects 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
239000008272 agar Substances 0.000 description 1
229940023476 agar Drugs 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
229960004607 alfuzosin Drugs 0.000 description 1
WNMJYKCGWZFFKR-UHFFFAOYSA-N alfuzosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CCCNC(=O)C1CCCO1 WNMJYKCGWZFFKR-UHFFFAOYSA-N 0.000 description 1
125000002723 alicyclic group Chemical group 0.000 description 1
150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
125000005910 alkyl carbonate group Chemical group 0.000 description 1
150000008052 alkyl sulfonates Chemical class 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
125000003435 aroyl group Chemical group 0.000 description 1
206010003119 arrhythmia Diseases 0.000 description 1
230000006793 arrhythmia Effects 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
239000000605 aspartame Substances 0.000 description 1
235000010357 aspartame Nutrition 0.000 description 1
IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
229960003438 aspartame Drugs 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
239000000440 bentonite Substances 0.000 description 1
229910000278 bentonite Inorganic materials 0.000 description 1
229940092782 bentonite Drugs 0.000 description 1
235000012216 bentonite Nutrition 0.000 description 1
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
XFOZBWSTIQRFQW-UHFFFAOYSA-M benzyl-dimethyl-prop-2-enylazanium;chloride Chemical compound [Cl-].C=CC[N+](C)(C)CC1=CC=CC=C1 XFOZBWSTIQRFQW-UHFFFAOYSA-M 0.000 description 1
229940000635 beta-alanine Drugs 0.000 description 1
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
230000001588 bifunctional effect Effects 0.000 description 1
239000013060 biological fluid Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
HSUIVCLOAAJSRE-UHFFFAOYSA-N bis(2-methoxyethyl) benzene-1,2-dicarboxylate Chemical compound COCCOC(=O)C1=CC=CC=C1C(=O)OCCOC HSUIVCLOAAJSRE-UHFFFAOYSA-N 0.000 description 1
229920001400 block copolymer Polymers 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
229910021538 borax Inorganic materials 0.000 description 1
239000000872 buffer Substances 0.000 description 1
235000019437 butane-1,3-diol Nutrition 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
235000001465 calcium Nutrition 0.000 description 1
MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
239000001527 calcium lactate Substances 0.000 description 1
235000011086 calcium lactate Nutrition 0.000 description 1
229960002401 calcium lactate Drugs 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
125000001589 carboacyl group Chemical group 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
229940096529 carboxypolymethylene Drugs 0.000 description 1
239000000969 carrier Substances 0.000 description 1
229920006217 cellulose acetate butyrate Polymers 0.000 description 1
229920003086 cellulose ether Polymers 0.000 description 1
239000004927 clay Substances 0.000 description 1
238000000975 co-precipitation Methods 0.000 description 1
239000008199 coating composition Substances 0.000 description 1
239000003086 colorant Substances 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000013267 controlled drug release Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000007822 coupling agent Substances 0.000 description 1
229960005168 croscarmellose Drugs 0.000 description 1
229960000913 crospovidone Drugs 0.000 description 1
239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
WJTCGQSWYFHTAC-UHFFFAOYSA-N cyclooctane Chemical compound C1CCCCCCC1 WJTCGQSWYFHTAC-UHFFFAOYSA-N 0.000 description 1
239000004914 cyclooctane Substances 0.000 description 1
229940119744 dextran 40 Drugs 0.000 description 1
UCVPKAZCQPRWAY-UHFFFAOYSA-N dibenzyl benzene-1,2-dicarboxylate Chemical compound C=1C=CC=C(C(=O)OCC=2C=CC=CC=2)C=1C(=O)OCC1=CC=CC=C1 UCVPKAZCQPRWAY-UHFFFAOYSA-N 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
HBGGXOJOCNVPFY-UHFFFAOYSA-N diisononyl phthalate Chemical compound CC(C)CCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCC(C)C HBGGXOJOCNVPFY-UHFFFAOYSA-N 0.000 description 1
FBSAITBEAPNWJG-UHFFFAOYSA-N dimethyl phthalate Natural products CC(=O)OC1=CC=CC=C1OC(C)=O FBSAITBEAPNWJG-UHFFFAOYSA-N 0.000 description 1
PSHRANCNVXNITH-UHFFFAOYSA-N dimethylamino acetate Chemical compound CN(C)OC(C)=O PSHRANCNVXNITH-UHFFFAOYSA-N 0.000 description 1
229960001826 dimethylphthalate Drugs 0.000 description 1
235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
150000002009 diols Chemical class 0.000 description 1
238000007907 direct compression Methods 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
230000006806 disease prevention Effects 0.000 description 1
YHAIUSTWZPMYGG-UHFFFAOYSA-L disodium;2,2-dioctyl-3-sulfobutanedioate Chemical compound [Na+].[Na+].CCCCCCCCC(C([O-])=O)(C(C([O-])=O)S(O)(=O)=O)CCCCCCCC YHAIUSTWZPMYGG-UHFFFAOYSA-L 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
229960001389 doxazosin Drugs 0.000 description 1
RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
229920001971 elastomer Polymers 0.000 description 1
239000003974 emollient agent Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
230000001856 erectile effect Effects 0.000 description 1
IFDFMWBBLAUYIW-UHFFFAOYSA-N ethane-1,2-diol;ethyl acetate Chemical compound OCCO.CCOC(C)=O IFDFMWBBLAUYIW-UHFFFAOYSA-N 0.000 description 1
230000029142 excretion Effects 0.000 description 1
239000000835 fiber Substances 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000013020 final formulation Substances 0.000 description 1
235000019138 food restriction Nutrition 0.000 description 1
235000019256 formaldehyde Nutrition 0.000 description 1
229960002737 fructose Drugs 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
238000001879 gelation Methods 0.000 description 1
239000003349 gelling agent Substances 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
KMZHZAAOEWVPSE-UHFFFAOYSA-N glycerol monoacetate Natural products CC(=O)OCC(O)CO KMZHZAAOEWVPSE-UHFFFAOYSA-N 0.000 description 1
239000001087 glyceryl triacetate Substances 0.000 description 1
235000013773 glyceryl triacetate Nutrition 0.000 description 1
150000002337 glycosamines Chemical class 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
DZZRNEZNZCRBOT-UHFFFAOYSA-N hexane-1,2,4-triol Chemical compound CCC(O)CC(O)CO DZZRNEZNZCRBOT-UHFFFAOYSA-N 0.000 description 1
AAYGSSGHJGVNSK-UHFFFAOYSA-N hexane-1,3,6-triol Chemical compound OCCCC(O)CCO AAYGSSGHJGVNSK-UHFFFAOYSA-N 0.000 description 1
XXMIOPMDWAUFGU-UHFFFAOYSA-N hexane-1,6-diol Chemical compound OCCCCCCO XXMIOPMDWAUFGU-UHFFFAOYSA-N 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
229920001519 homopolymer Polymers 0.000 description 1
239000003906 humectant Substances 0.000 description 1
235000003642 hunger Nutrition 0.000 description 1
230000002706 hydrostatic effect Effects 0.000 description 1
229940071676 hydroxypropylcellulose Drugs 0.000 description 1
208000021822 hypotensive Diseases 0.000 description 1
230000001077 hypotensive effect Effects 0.000 description 1
239000012442 inert solvent Substances 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000007924 injection Substances 0.000 description 1
229910001867 inorganic solvent Inorganic materials 0.000 description 1
239000003049 inorganic solvent Substances 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
229940011051 isopropyl acetate Drugs 0.000 description 1
GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
239000004922 lacquer Substances 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000004571 lime Substances 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
INHCSSUBVCNVSK-UHFFFAOYSA-L lithium sulfate Inorganic materials [Li+].[Li+].[O-]S([O-])(=O)=O INHCSSUBVCNVSK-UHFFFAOYSA-L 0.000 description 1
KAGBQTDQNWOCND-UHFFFAOYSA-M lithium;chlorite Chemical compound [Li+].[O-]Cl=O KAGBQTDQNWOCND-UHFFFAOYSA-M 0.000 description 1
229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
229960003194 meglumine Drugs 0.000 description 1
229940041616 menthol Drugs 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
CXHHBNMLPJOKQD-UHFFFAOYSA-N methyl hydrogen carbonate Chemical compound COC(O)=O CXHHBNMLPJOKQD-UHFFFAOYSA-N 0.000 description 1
229960002900 methylcellulose Drugs 0.000 description 1
239000003607 modifier Substances 0.000 description 1
238000000465 moulding Methods 0.000 description 1
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
MCSAJNNLRCFZED-UHFFFAOYSA-N nitroethane Chemical compound CC[N+]([O-])=O MCSAJNNLRCFZED-UHFFFAOYSA-N 0.000 description 1
230000002746 orthostatic effect Effects 0.000 description 1
208000020629 overactive bladder Diseases 0.000 description 1
230000035515 penetration Effects 0.000 description 1
239000008180 pharmaceutical surfactant Substances 0.000 description 1
235000011007 phosphoric acid Nutrition 0.000 description 1
150000003016 phosphoric acids Chemical class 0.000 description 1
125000005498 phthalate group Chemical class 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
239000006069 physical mixture Substances 0.000 description 1
229960000502 poloxamer Drugs 0.000 description 1
229920001993 poloxamer 188 Polymers 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
229920002492 poly(sulfone) Polymers 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920000058 polyacrylate Polymers 0.000 description 1
229920001281 polyalkylene Polymers 0.000 description 1
229920001515 polyalkylene glycol Polymers 0.000 description 1
229920001748 polybutylene Polymers 0.000 description 1
229920000515 polycarbonate Polymers 0.000 description 1
239000004417 polycarbonate Substances 0.000 description 1
229920000728 polyester Polymers 0.000 description 1
229940068886 polyethylene glycol 300 Drugs 0.000 description 1
229920002959 polymer blend Polymers 0.000 description 1
239000002861 polymer material Substances 0.000 description 1
239000004926 polymethyl methacrylate Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
229940100528 polyoxyl 8 stearate Drugs 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
229920000166 polytrimethylene carbonate Polymers 0.000 description 1
229920002635 polyurethane Polymers 0.000 description 1
239000004814 polyurethane Substances 0.000 description 1
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
229910052573 porcelain Inorganic materials 0.000 description 1
239000011148 porous material Substances 0.000 description 1
239000011698 potassium fluoride Substances 0.000 description 1
235000003270 potassium fluoride Nutrition 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
229940116317 potato starch Drugs 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
238000004080 punching Methods 0.000 description 1
HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
238000012552 review Methods 0.000 description 1
102220310434 rs764401457 Human genes 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
239000002356 single layer Substances 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
235000017550 sodium carbonate Nutrition 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical group [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
239000011775 sodium fluoride Substances 0.000 description 1
235000013024 sodium fluoride Nutrition 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
IJRHDFLHUATAOS-DPMBMXLASA-M sodium ricinoleate Chemical compound [Na+].CCCCCC[C@@H](O)C\C=C/CCCCCCCC([O-])=O IJRHDFLHUATAOS-DPMBMXLASA-M 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
235000010339 sodium tetraborate Nutrition 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
235000011071 sorbitan monopalmitate Nutrition 0.000 description 1
239000001570 sorbitan monopalmitate Substances 0.000 description 1
229940031953 sorbitan monopalmitate Drugs 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
241000894007 species Species 0.000 description 1
238000005507 spraying Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
235000011044 succinic acid Nutrition 0.000 description 1
150000003444 succinic acids Chemical class 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
230000001839 systemic circulation Effects 0.000 description 1
230000006794 tachycardia Effects 0.000 description 1
229960001693 terazosin Drugs 0.000 description 1
VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 description 1
RBTVSNLYYIMMKS-UHFFFAOYSA-N tert-butyl 3-aminoazetidine-1-carboxylate;hydrochloride Chemical compound Cl.CC(C)(C)OC(=O)N1CC(N)C1 RBTVSNLYYIMMKS-UHFFFAOYSA-N 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
VUYXVWGKCKTUMF-UHFFFAOYSA-N tetratriacontaethylene glycol monomethyl ether Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO VUYXVWGKCKTUMF-UHFFFAOYSA-N 0.000 description 1
239000000892 thaumatin Substances 0.000 description 1
235000010436 thaumatin Nutrition 0.000 description 1
OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
231100000816 toxic dose Toxicity 0.000 description 1
229960002622 triacetin Drugs 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
PVNIQBQSYATKKL-UHFFFAOYSA-N tripalmitin Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 description 1
BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
238000005406 washing Methods 0.000 description 1
239000005019 zein Substances 0.000 description 1
229940093612 zein Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CZ200415532U 2003-11-10 2004-06-09 Farmaceutická kompozice s postupným uvolňováním CZ15015U1 (cs)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP2003380442		2003-11-10

Publications (1)

Publication Number	Publication Date
CZ15015U1 true CZ15015U1 (cs)	2005-01-13

Family

ID=34225356

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CZ200415532U CZ15015U1 (cs)	2003-11-10	2004-06-09	Farmaceutická kompozice s postupným uvolňováním

Country Status (4)

Country	Link
US (1)	US8197846B2 (fr)
EP (1)	EP1568361A3 (fr)
CZ (1)	CZ15015U1 (fr)
SK (1)	SK4325U (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20060062845A1 (en) *	2004-09-17	2006-03-23	Cimex Pharma Ag	Alfuzosin tablets and synthesis
WO2007072495A2 (fr) *	2005-11-03	2007-06-28	Sun Pharmaceutical Industries Limited	Comprimes enrobes a liberation controlee caracterises par une retention gastrique prolongee
WO2007131804A1 (fr) *	2006-05-17	2007-11-22	Synthon B.V.	Composition en comprimé pour la libération prolongée de la tamsulosine
CN100536838C (zh) *	2006-09-22	2009-09-09	北京红林制药有限公司	一种盐酸坦洛新控释片制剂及其制备方法
EP2067475A4 (fr) *	2006-09-26	2010-12-15	Astellas Pharma Inc	Préparation à libération entretenue de tacrolimus
CN100563637C (zh) *	2006-10-13	2009-12-02	北京红林制药有限公司	一种控释给药的药芯组合物和控释制剂及其制备方法
WO2008084698A1 (fr) *	2006-12-28	2008-07-17	Astellas Pharma Inc.	Composition pharmaceutique à libération entretenue de tacrolimus
EP2042169A1 (fr) *	2007-09-26	2009-04-01	LEK Pharmaceuticals D.D.	Tablettes d'hydrochlorure de tamsulosin à libération contrôlée et son processus de fabrication
AU2008305243B2 (en) *	2007-09-28	2013-09-12	Lintec Corporation	Medicinal preparation for oral administration
EP2047847A1 (fr)	2007-10-12	2009-04-15	KRKA, tovarna zdravil, d.d., Novo mesto	Composition pharmaceutique solide comprenant de la tamsulosine
ATE551998T1 (de) *	2007-10-12	2012-04-15	Krka Tovarna Zdravil D D Novo Mesto	Feste pharmazeutische zusammensetzung mit tamsulosin
JP2012500221A (ja) *	2008-08-15	2012-01-05	ディポメド，インコーポレイティド	Ｃｎｓ障害の処理及び予防のための胃保持性医薬組成物
TWI478712B (zh) *	2008-09-30	2015-04-01	Astellas Pharma Inc	釋控性醫藥組成物
US8465770B2 (en) *	2008-12-24	2013-06-18	Synthon Bv	Low dose controlled release tablet
PL2394648T3 (pl)	2009-02-04	2016-12-30		Kompozycja farmaceutyczna do podawania doustnego
EP2255793A1 (fr)	2009-05-28	2010-12-01	Krka Tovarna Zdravil, D.D., Novo Mesto	Composition pharmaceutique comprenant du tamsulosine
WO2011122523A1 (fr) *	2010-03-29	2011-10-06	アステラス製薬株式会社	Composition pharmaceutique à libération contrôlée
WO2011122524A1 (fr)	2010-03-29	2011-10-06	アステラス製薬株式会社	Composition pharmaceutique à libération contrôlée
CA2902424A1 (fr)	2013-03-14	2014-09-25	Amgen Inc.	Composes heterocycliques et leurs utilisations
AR101476A1 (es)	2014-08-07	2016-12-21	Acerta Pharma Bv	Métodos para tratar cánceres, enfermedades inmunes y autoinmunes, y enfermedades inflamatorias en base a la tasa de ocupación de la tirosin quinasa de bruton (btk) y a la tasa de resíntesis de la tirosin quinasa de bruton (btk)
TWI722988B (zh) *	2015-06-05	2021-04-01	瑩碩生技醫藥股份有限公司	緩釋性醫藥組合物及其製備方法
US10751293B2 (en) *	2015-09-03	2020-08-25	Case Western Reserve University	Polymer fiber scaffolds and uses thereof
US20190133977A1 (en) *	2016-05-04	2019-05-09	Aspen Park Pharmaceuticals, Inc.	Delayed release oral tamsulosin hydrochloride
EP3473244A1 (fr)	2017-10-20	2019-04-24	Veru Inc.	Chlorhydrate de tamsulosine à libération contrôlée destiné à être administré par voie orale
EP3473245A1 (fr)	2017-10-20	2019-04-24	Veru Inc.	Chlorhydrate de tamsulosine à libération contrôlée destiné à être administré par voie orale
US12097189B1 (en)	2024-02-09	2024-09-24	Astellas Pharma Inc.	Pharmaceutical composition for modified release

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4772475A (en) *	1985-03-08	1988-09-20	Yamanouchi Pharmaceutical Co., Ltd.	Controlled-release multiple units pharmaceutical formulation
JP3140465B2 (ja)	1992-09-18	2001-03-05	山之内製薬株式会社	ハイドロゲル徐放性製剤
TW536402B (en)	1998-06-26	2003-06-11	Yamanouchi Pharma Co Ltd	Pharmaceutical composition for the therapy of voiding dysfunction
US6423719B1 (en) *	1999-02-16	2002-07-23	Upsher-Smith Laboratories, Inc.	Method for treating benign prostate hyperplasia
US20030104048A1 (en) *	1999-02-26	2003-06-05	Lipocine, Inc.	Pharmaceutical dosage forms for highly hydrophilic materials
US6562375B1 (en) *	1999-08-04	2003-05-13	Yamanouchi Pharmaceuticals, Co., Ltd.	Stable pharmaceutical composition for oral use
WO2002062389A1 (fr) *	2001-02-08	2002-08-15	Ono Pharmaceutical Co., Ltd.	Remedes pour des maladies urinaires contenant des agents de regulation du recepteur de lpa
KR100530546B1 (ko)	2001-07-27	2005-11-23	아스텔라스세이야쿠 가부시키가이샤	구강내에서 신속하게 붕괴되는 정제용 서방성 미립자가함유된 조성물 및 그의 제조 방법
JP2005512997A (ja) *	2001-11-07	2005-05-12	シントン・ベスローテン・フェンノートシャップ	タムスロシン錠
KR101132969B1 (ko)	2001-11-13	2012-04-09	아스텔라스세이야쿠 가부시키가이샤	용해성 약물 지속 방출 시스템
CN100355419C (zh)	2002-06-07	2007-12-19	安斯泰来制药有限公司	治疗膀胱过度活动的药物
US20040091528A1 (en) *	2002-11-12	2004-05-13	Yamanouchi Pharma Technologies, Inc.	Soluble drug extended release system
US7442387B2 (en) *	2003-03-06	2008-10-28	Astellas Pharma Inc.	Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
US7611728B2 (en) *	2003-09-05	2009-11-03	Supernus Pharmaceuticals, Inc.	Osmotic delivery of therapeutic compounds by solubility enhancement
WO2005030179A1 (fr)	2003-09-29	2005-04-07	Cj Corporation	Formulations a liberation lente
KR100436701B1 (ko) *	2003-11-07	2004-06-22	주식회사 씨티씨바이오	염산 탐스로신 함유 방출 조절형 제제 및 그의 제조방법
US8128958B2 (en) *	2003-11-10	2012-03-06	Astellas Pharma Inc.	Sustained release pharmaceutical composition
US7387793B2 (en) *	2003-11-14	2008-06-17	Eurand, Inc.	Modified release dosage forms of skeletal muscle relaxants

2004
- 2004-05-10 US US10/842,809 patent/US8197846B2/en not_active Expired - Fee Related
- 2004-06-09 CZ CZ200415532U patent/CZ15015U1/cs not_active IP Right Cessation
- 2004-06-09 SK SK159-2004U patent/SK4325U/sk unknown
- 2004-06-09 EP EP04013655A patent/EP1568361A3/fr not_active Withdrawn

Also Published As

Publication number	Publication date
US20050100602A1 (en)	2005-05-12
EP1568361A3 (fr)	2006-02-22
US8197846B2 (en)	2012-06-12
SK4325U (sk)	2005-12-01
EP1568361A2 (fr)	2005-08-31

Legal Events

Date	Code	Title	Description
2005-03-16	FG1K	Utility model registered	Effective date: 20050113
2008-06-04	ND1K	First or second extension of term of utility model	Effective date: 20080507
2011-06-08	ND1K	First or second extension of term of utility model	Effective date: 20110523
2014-06-18	MK1K	Utility model expired	Effective date: 20140609

Publication	Publication Date	Title
CZ15015U1 (cs)	2005-01-13	Farmaceutická kompozice s postupným uvolňováním
KR100618234B1 (ko)	2006-09-01	다공성 입자를 포함하는 제형
US8128958B2 (en)	2012-03-06	Sustained release pharmaceutical composition
US11707451B2 (en)	2023-07-25	Pharmaceutical composition for modified release
JP4500679B2 (ja)	2010-07-14	パリペリドンを制御送達する方法および投薬形態物
ZA200603304B (en)	2007-11-28	OROS push-stick for controlled delivery of active agents
US20110281906A1 (en)	2011-11-17	Sustained release formulation for tacrolimus
KR20030024844A (ko)	2003-03-26	히드로겔 구동되는 약물 제형
JP2003518489A (ja)	2003-06-10	ヒドロゲル駆動の薬物剤形
JP5849946B2 (ja)	2016-02-03	放出制御医薬組成物
JP2005162736A (ja)	2005-06-23	徐放性医薬組成物
JP2005162737A (ja)	2005-06-23	徐放性医薬組成物
US10213387B2 (en)	2019-02-26	Oral drug delivery system
US12097189B1 (en)	2024-09-24	Pharmaceutical composition for modified release
US20080206338A1 (en)	2008-08-28	Controlled release formulations of an alpha-adrenergic receptor antagonist
DE202004009564U1 (de)	2005-01-13	Pharmazeutische Zusammensetzung mit nachhaltiger Freisetzung
DE202004009563U1 (de)	2004-11-11	Pharmazeutische Zusammensetzung mit nachhaltiger Freisetzung